1. Introduction {#s0005}
===============

Pulmonary fibrosis (PF) is a serious lung disorder characterized by excessive accumulation of extracellular matrix (ECM) ([@bib133], [@bib7]). In the early period of PF, the affected lungs are mainly inflammatory cell infiltration, edema and congestion, and then converted to the injury of alveolar epithelial cells (AEC), abnormal proliferation of ECM-producing cells (mesenchymal cells including fibroblasts (FB) and myofibroblasts (MFb)), the overproduction of ECM (collagens, laminin, tenascin-C, *etc*.), resulting in progressive scarring and loss of lung function ([@bib101], [@bib69], [@bib21]). Up to now, lots of studies have shown that the molecular mechanisms of PF is involved in the superabundant inflammation such as cytokines release and inflammasome activation ([@bib43]), macrophages activation ([@bib75]), FB to MFb transformation ([@bib132]), epithelial-mesenchymal transition (EMT, converting from epithelial phenotype to fibroblastic phenotype) ([@bib69]), matrix metalloproteinase (MMP)/(tissue inhibitor of metalloproteinase (TIMP)) balance ([@bib163]), oxidative stress ([@bib11]) and several signaling pathways activation ([@bib14], [@bib16]) ( [Fig. 1](#f0005){ref-type="fig"}). It is confirmed that one of the main pathological mechanisms of PF is the imbalance between the synthesis and degradation of ECM, while the degradation of ECM is mainly regulated by MMP and TIMP ([@bib163]). The most components of ECM is degraded by MMP; TIMP is a primary inhibitor of MMP, while the overproduction of TIMP aggravates the fibrosis ([@bib163]). During EMT, the down-regulated levels of epithelial markers (such as E-cadherin) and up-regulated levels of mesenchymal cells markers (such as α-smooth muscle actin (α-SMA), vimentin, N-cadherin, fibronectin (FN)) as well as the signaling proteins transforming growth factor (TGF)-β1, Smads, and phosphorylated Smads (*p*-Smads), are concomitant with the ability of epithelial cells to adopt mesenchymal phenotypes ([@bib58]). Thus, the agents targeting these events may promote the development of PF treatment.Fig. 1The pathological mechanisms of pulmonary fibrosis. A series of factors (drugs, IR or else) trigger the continuous development of pulmonary fibrosis by inducing cell stress *via* superabundant inflammation, macrophages activation, abnormal FB proliferation, FB to MFb transformation, EMT and oxidative stress, resulting in excessive ECM accumulation and persistent fibrosis.Fig. 1

It is well known that the treatment options of lung fibrosis include the anti-oxidants, cytokine inhibitors, anti-fibrotic agents and lung transplantation or else ([@bib96]). However, these are confined to mostly focusing on one or two aspects in the process of lung injury and repair. The widely accepted therapeutic schedule for PF with the serial therapy of corticosteroids, immunosuppressive drugs plus anti-oxidants (N-acetylcysteine), may be no longer appropriate ([@bib8]). Though pirfenidone has been demonstrated preferable activity for treating PF in clinical, it receives only a conditional recommendation for use and, the effectiveness and safety for long-time use is unknown yet ([@bib92], [@bib102]). Thus, further efforts are still urgently needed to develop novel strategies to prevent this refractory respiratory disease. Traditional Chinese medicine (TCM), one of the main parts of the medical practice, is just as a natural chemical library which produce synergistic effects through the synergistic mechanism, enhanced functions and less toxicity of the principle active ingredients ([@bib9], [@bib35], [@bib36], [@bib105], [@bib155]). It often exerts wider action spectrum in managing the medical disorders either as mono-therapy or in combination with standard Western medical treatment ([@bib13], [@bib73], [@bib143], [@bib155]). Moreover, the single herbs and herbal formulations have provided a vast source for drug discovery such as Artemisinin ([@bib118]) and Berberine ([@bib53]), in treating human diseases.

Recently, emerging researches have been conducted to investigate the efficacy of TCM in the treatment of PF. With regard to the applied *in vivo* PF models, bleomycin (BLM) remains the most used experimental tool to evaluate the pathogenetic mechanisms and new therapeutic approaches for acute lung injury and fibrosis, including the exploration of TCM ([@bib131], [@bib12], [@bib103]). It has been proven that the active agents from TCM, in particular, the flavonoids, terpenes and alkaloids, exhibit potential benefits for PF, the biological effects of which appear to involve the regulation of inflammation, oxidant stress, and pro-fibrotic signaling pathways. Here, we highlight the recent advances of the anti-fibrotic agents from TCM in the prevention of PF and their proposed biological effects, and summarize future perspectives on such work, hoping to provide a promising view in the discovery of the anti-fibrotic compounds from further evaluation and application of TCM in the management of PF.

2. Methods {#s0010}
==========

The literature materials were obtained from the scientific databases including the Pubmed, SpringerLink, Web of Science and CNKI databases (up to Aug 2016), and was to identify the studies on the anti-fibrotic role of the active agents from TCM as well as the possible mechanisms. The search keywords for these work included "lung fibrosis" or "pulmonary fibrosis", and "traditional Chinese medicine", "extract" or "herb" in all fields. The names of the chemical components listed in present review are corresponding to that in the journal plant list. In a broader viewpoint, insights gained from these work can serve in expanding and improving the utilization of TCM in the development of PF treatment.

3. Single component from herbs for the therapy of PF {#s0015}
====================================================

Currently, emerging herbal medicines have been available for clinical therapy in diverse human diseases, even the single herb-derived agents that are widely used (e.g. taxol and flavoxate). It is reported in the ethnopharmacological studies that the single component from herbs have been proven possessing potential benefits in PF treatment, particularly, the monomers which belong to flavonoids, terpenes and alkaloids ( [Table 1](#t0005){ref-type="table"}).Table 1The studies of single component from herbs for the therapy of PF.Table 1**CategoriesMonomersHerbal sourcesObjects (model inducers, doses)Ref.*****In vitro****In vivo*****PF patients**FlavonoidsBaicalein*Scutellaria baicalensis* Georgi--SD rats (BLM, 5 mg/kg), ICR mice (BLM, 3.5 mg/kg)AMs[@bib117][@bib32] and [@bib44]Tectorigenin*Iris tectorum* Maxim.--SD rats (BLM, 7.5 U/kg)--[@bib151]Quercetin*Leonurus sibiricus* L.HELFs (SiO~2~, 50 μg/ml)SD rats (BLM, 5 U/kg)AMs[@bib6] and [@bib94]HSYA*Cathamus tinctorius* L.--Wistar rats (1 g/L LPS and cigarette smoke)--[@bib127]  TerpenoidsTriptolide*Tripterygium wilfordii* Hook F.MH-S AMs (IR, 2 Gy), NIH3T3 cells (TGF-β1, 5 ng/ml)C57BL/6 mice (IR, 15 Gy)--[@bib15]Celastrol--Wistar rats (BLM, 3 U/kg)--[@bib25]Paclitaxel*Taxus brevifolia* Nutt.A549, RLE-6TN AEC (TGF-β1, 5 ng/ml)SD rats (BLM, 5 mg/kg)--[@bib121] and [@bib162]ESA*Eclipta prostrata* L.--ICR mice (BLM, 5 mg/kg)--[@bib147]Tan IIA*Salvia miltiorrhiza* Bunge--SD rats (BLM, 5 mg/kg)--[@bib135] and [@bib41]GCA*Glycyrrhiza glabra* L.FB 3T6SD rats (BLM, 5 mg/kg)PF patients[@bib123][@bib31]Andro*Andrographis panicula* NeesH22 cellsKunming mice (BLM, 15 mg/kg)--[@bib38]  GlycosidesPaeoniflorin*Paeonia lactiflora* Pall.A549 AEC (TGF-β1, 2 ng/ml)ICR mice (BLM, 5 mg/kg)--[@bib48] and [@bib49]Naringin*Citrus paradisi* Macfad.--Kunming mice (PQ, 20, 30 or 50 mg/kg), Wistar rats (BLM, 5 mg/kg)--[@bib18][@bib120]Salidroside*Rhodiola rosea* L.A549, rat AEC (TGF-β1, 5, 10 ng/ml)SD rats (BLM, 5 mg/kg)--[@bib116]Astragalin*Diospyros kaki* L.f.BEAS−2B cells (H~2~O~2~, 20 μM)BALB/c mice (OVA, 20 μg)--[@bib20]  PhenolsResveratrol*Reynoutria japonica* Houtt.--Wistar rats (BLM, 2.5 mg/kg), ICR mice (LPS, 5 mg/kg)--[@bib2] and [@bib156]Curcumin*Curcuma longa* L.PMVEC, primary FB (IR, 2 Gy)C57BL/6 mice (0.5 μg LPS or 13.5 Gy IR), CBA/J mice (reovirus 1/L, 10^7^ PFU)FB (TGF-β, 6 ng/ml), PF patients[@bib64][@bib108][@bib5] and [@bib50]EGCG*Camellia sinensis* (L.) KuntzeFB WI−38 (TGF-β1, 10 ng/ml)Wistar rats (BLM, 6.5 U/kg), SD rats (IR, 22 Gy)--[@bib111], [@bib112], [@bib113] and [@bib146]Corilagin*Caesalpinia coriaria* (Jacq.) Willd.--BALB/c mice (BLM, 1 mg/ml)--[@bib129]Gallic acid*Areca catechu* L.--Wistar rats (BLM, 7.5 U/kg)--[@bib87]SAA*Salvia miltiorrhiza* BungeFB 3T6Wistar rats (BLM, 5 mg/kg)--[@bib91]SABFB MRC-5 (TGF-β1, 10 ng/ml)----[@bib154]  AlkaloidsNeferine*Nelumbo nucifera* Gaertn.RAW264.7 cells (BLM, 1 μg/ml)Kunming mice (0.1 mg BLM per mouse or 6.25 mg/kg amiodarone)--[@bib158] and [@bib88]Isoliensinine--Kunming mice (BLM, 0.1 mg per mouse)--[@bib137]THPCorydalis *yanhusuo* W.T.Wang--SD rats (IR, 15 Gy)--[@bib148]Oxymatrine*Sophora flavescens* Ait.--C57BL/6 mice (BLM, 3 mg/kg)--[@bib76]  Other monomersOsthole*Cnidium monnieri* (L.) Cusson--SD rats (BLM, 5 mg/kg)--[@bib39]GBA*Garcinia hanburyi* Hook.f.A549 AEC, HPMECs, FB HLF-1 (5 ng/ml TGF-β1, 100 μM CoCl~2~ or 2% O~2~)SD rats (BLM, 5 mg/kg)--[@bib98][^1]

3.1. Flavonoids {#s0020}
---------------

Baicalein (BAI) is a natural plant flavone that exhibits various biological activities. BAI (0.1--100 μM) could inhibit the oxidative and arachidonate metabolism of alveolar macrophages (AMs) which were from the bronchoalveolar lavage of patients with PF ([@bib117]). In a rat model, orally administered daily with BAI (50, 100 mg/kg) from day 1--28 after BLM exposure lowered the degree of PF, remarkably decreased the levels of Hyp (the main element of collagens), a-SMA (a MFb marker protein), miRNA (miR)-21, TGF-β1 and p-Smad2/3, but the total antioxidant capacity (T-AOC, an antioxidant indicator) was higher than in those without BAI treatment ([@bib32]). Further evidence showed that BAI treatment not only entirely restored the normal liver lipid profile, but also greatly improved the fat abundance and composition in an animal model induced by BLM, but not with dexamethasone, a commonly used glucocorticoids for treatment of PF ([@bib44]). These protective effects might be achieved by repressed inflammation, improved antioxidant activity, miR-21 function and TGF-β/Smad signaling pathway, as well as fewer adverse effects on liver lipid disorder ([@bib32], [@bib44], [@bib117]). Nevertheless, more researches are still needed to present its anti-fibrotic effects including the studies on different *in vitro* and *in vivo* models as well as the lacked clinical trails.

Tectorigenin is a type of O-methylated isoflavone. It significantly inhibited the proliferation of lung FB in BLM-treated rats ([@bib151]). Moreover, tectorigenin remarkably enhanced miR-338\* expression of lung FB and down-regulated the levels of FB matrix proteins procollagen type 1 a1 (COL1A1) and FN, and lysophosphatidic acid receptor 1 (LPA1), which is involved in many biological responses such as cell differentiation and apoptosis. This indicates a potential inhibitory role of tectorigenin on the pathogenesis of PF, however, there is scarcely any data related to its role in lung patients.

Quercetin is also a flavonoid found in a wide variety of plants that presents wide ranges of biological activities. It was clinically observed that frequent intake of quercetin-rich foods was inversely associated with the risk of lung cancer patients ([@bib61]). To evaluate the preventative effects of quercetin on BLM-induced PF *in vivo*, liposomal quercetin was intravenously injected 1 day prior to BLM administration and continued to the end of the study (for 4 weeks) ([@bib6]). As a result, the increased macrophage counts, and the neutrophil and lymphocyte counts in bronchoalveolar lavage fluid (BALF) were diminished both on day 7 and 14 in liposomal quercetin treated group compared with BLM-induced group ([@bib6]). Meanwhile, the levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6 in BALF at day 7 were strikingly reduced after liposomal quercetin treatment. Moreover, treatment with liposomal quercetin apparently lessened the PF areas and collagen deposition accompanied with decreased TGF-β1 expression by histopathological assessment. However, the histopathological assessment and cell counts in BALF showed that there were no significant differences between liposomal quercetin-treated and BLM model groups when applying late therapeutic strategies with administrated liposomal quercetin after BLM being intratracheally injected for 7 days. It suggested that the main role of liposomal quercetin was on reducing the initial injury responses triggered by BLM, but not the level of fibrosis after the proinflammatory responses occurred and developed ([@bib6]). In another study of human embryonic lung fibroblasts (HELFs) which were incubated with the cultured supernatant of AMs that collected from the BALF of PF patients, quercetin (20, 40 μmol/L) could significantly reverse the decreased MMP-1 expression and increased TIMP-1 production that induced by SiO~2~ ([@bib94]). These data show that quercetin may provide a strategy for protecting PF patients but more clinical studies is still needed.

Safflor yellow (SY) is the aqueous extract of safflower (*Carthamus tinctorius* L.) and its injection has been used to treat myocardial ischemia in the clinical of China for many years. Hydroxy safflor yellow A (HSYA) is the bioactive ingredient of SY and safflower. It has been reported effective to treat acute cerebral infarction patients ([@bib65]). Further study investigated the effect of HSYA on small airway remodeling in a rat model induced by cigarette smoke and lipopolysaccharide (LPS) ([@bib127]). HSYA was reported to significantly attenuate the thickening and collagen deposition of the small airway and inhibit TGF-β1 protein expression and phosphorylation of p38 mitogen-activated protein kinases (MAPK, involves the production of pro-inflammatory and pro-fibrotic mediators) in the lung tissue of rats, indicating the potential benefit of HSYA on attenuating the pathological airway remodeling ([@bib127]). However, no direct role of HSYA on PF patients is shown yet.

3.2. Terpenoids {#s0025}
---------------

Triptolide (TPL) is a diterpenoid epoxide. Previous clinical trials evaluated that TPL in combination with procaterol and theophylline is effective for the treatment of steroid-resistant asthma ([@bib51]). Lately, other authors established an irradiation (IR)-induced PF in C57BL/6 mice with 15 Gy on whole chest and then the mice were treated without or with TPL (*i.v*. 0.25 mg/kg, qod for 1 month) ([@bib15]). It demonstrated that TPL effectively reduced the IR-induced PF as evidenced by the less MFb, collagen deposition, ROS, and infiltrated AMs in the IR-lung tissue, as well as declined levels of NADPH oxidase (NOX)-2 and NOX-4 in AMs ([@bib15]). Its potential role in PF patients is encouraged to be included in the ongoing studies.

Celastrol is a quinine-methide tri-terpenoid which is derived from *Tripterygium wilfordii* Hook F. It was observed that BLM (3 U/kg bw)-induced rats exhibited morphological abnormalities with decreased levels of enzymatic antioxidants (superoxide dismutases (SOD), catalase (CAT), glutathione peroxidases (GPx), glutathione reductase (GR)) and non-enzymatic antioxidants (glutathione (GSH), Vitamin C and E), nonetheless, above conditions were prominently suppressed upon celastrol (5 mg/kg) treatment ([@bib25]). In addition, celastrol treatment enhanced the expression of nuclear factor erythroid 2-related factor (Nrf2) and heme oxygenase-1 (HO-1), but decreased the activities of MMP2 and MMP9, count of mast cells, and levels of TNF-α, histamine and serotonin. These observations support that celastrol protects against BLM-induced PF by inhibiting inflammation and enhancing antioxidant ability which probably through the activation of Nrf2. Celastrol therefore potentially be used as an anti-fibrotic agent, but it has not been appeared or used in the studies of human diseases.

Paclitaxel (PTX) is a complex diterpene alkaloid. PTX and carboplatin combination chemotherapy was shown effective and safe in advanced non-small cell lung cancer patients ([@bib81]). Wang and colleagues investigated the anti-fibrotic effect of the low-dose PTX (10--50 nM *in vitro*, and 0.6 mg/kg *in vivo*) ([@bib121]). This research showed that PTX treatment resulted in the amelioration of BLM-induced PF in rats with reduction of lung index and collagen deposition. Besides, PTX treatment resulted in EMT phenotypic reversion and normalization of vimentin, E-cadherin, Smad3 and p-Smad3 expression, while A549 AEC treated with PTX, in majority, were resistant to the TGF-β1-induced EMT, whereas PTX-untreated controls are more vulnerable to EMT. Through decreasing Smad3/p-Smad3 expression and up-regulating miR-140, PTX treatment could significantly reverse the EMT of AEC and prevent PF of rats, demonstrating the suppression of TGF-β1/Smad3 pathway *via* up-regulating miR-140 with low-dose PTX in preventing PF ([@bib121]). A recent study declared that PTX liposome inhalation in rats, could improve survival rate and PF Ashcroft score, and decreased the thickness of the alveolar interval as well as the levels of collagen type I (Col-I) and III and TGF-β1 expression ([@bib162]). Thus, the clinical attempt of PTX in PF may be a meaningful practice for the development of new drugs.

*Eclipta prostrata* L. is considered as a nourishing herbal medicine with pleiotropic effects. In a Chinese medical practice report with 50 patients, a large dose of fresh *Eclipta prostrata* L. in combination with a small amount of the peels from *Citrus reticulata Blanco* has a good curative effect on the treatment of chronic bronchitis patients ([@bib70]). [@bib147]) recently carried out a research of *Eclipta prostrata* extract (EXT, 2.5, 1.25, 0.625 g/kg, oral) and one of its main triterpene glycosides component eclipta saponin A (ESA, 80 mg/kg, oral) on BLM-induced mice model. The authors declared that EXT treatment not only ameliorated BLM-induced lung pathological changes, weight loss, mortality, and lung index, but also evidently reduced the lung Hyp and malondialdehyde (MDA, an indicator of lipid peroxidation) content, alleviated the levels of cyclooxygenase (COX)-2, TGF-β1, MMP-2 and α-SMA, as well as elevated the ratio value of MMP-9/TIMP-1, enhanced the lung SOD activity ([@bib147]). Besides, the survival rate, loss of body weight and lung index were not significantly improved by ESA administration, but the Hyp level and the score of inflammation and fibrosis in lung tissue were significantly reduced after 14 days treatment with ESA at the same dose. ESA could also block the up-regulated expression of TGF-β1 and α-SMA induced by BLM for 28 days. These data show that *Eclipta prostrata* has protective effects against PF induced by BLM possibly *via* reducing oxidative stress, tissue inflammation, and the subsequent EMT, which may be involved with the triterpenoid saponins, such as ESA.

Tanshinone IIA (Tan IIA) is an important lipophilic diterpene. It has been clinically proven effective in treating the patients with liver fibrosis ([@bib89]) and severe pneumonia ([@bib138]). [@bib135]) provided further evidence that Tan IIA treatment notably decreased the expression of TGF-β1, reversed the reduced production of angiotensin converting enzyme (ACE)-2 and its enzymatic product angiotensin (ANG)-(1--7) in rats' lungs induced by BLM. It indicates the protective effects of Tan IIA on experimental PF may also ascribe to regulate the ACE-2/ANG-(1--7) axis, which plays a key negative regulatory factor for patients with severity of lung edema ([@bib59]) and acute lung failure ([@bib46]). Subsequently, treatment with Tan IIA markedly attenuated the severe lung edema, inflammation and fibrosis in the BLM-treated rats with significantly decreased counts of total cells, neutrophils and lymphocytes in BALF ([@bib41]). In addition, BLM-induced increased expression of TNF-α, IL-1β, IL-6, COX-2, prostaglandin (PG) E2, malondialdehyde (MDA, an indicator of lipid peroxidation), iNOS and NO in rats was also suppressed by Tan IIA injection. This demonstrates that Tan IIA reduces BLM-induced inflammatory cell infiltration, pro-inflammatory cytokine release and excessive collagen deposition in rats, while the exerted effect may be *via* modulating NO production during the development of PF ([@bib41]). These clinical and pre-clinical contribution of Tan IIA should drive future efforts on PF patients.

Glycyrrhizic acid (GCA) has been demonstrated by modern scientific approaches to possess a wide spectrum of pharmaceutical properties, such as anti-inflammatory, anti-diabetic, anti-oxidant, anti-tumor, anti-microbial, and anti-viral properties ([@bib82]). From a work with 42 cases of PF patients, intravenous drip with GCA diamine (300 mg daily for 4 weeks) in combination with its capsules (150 mg daily for another 5 months) could significantly reduce the serum levels of hyaluronic acid and procollagen III along with slight adverse reactions (edema, heart palpitations, increased blood pressure) in PF patients, when compared to those treated with prednisone (0.5 mg/kg daily for 4 weeks and 0.125 mg/kg daily for another 5 months) ([@bib123]). Recent experimental study revealed that GCA treatment (50, 100, 200 mg/kg bw/d) could ameliorate BLM-induced local fibrotic lesions and lung edema with mild thickening of the lung interstitium, remarkably reduced the areas of collagen deposition (by Masson staining) and the contents of Col-I and Hyp in the lung in a dose-dependent manner ([@bib31]). Following 28-days GCA treatment, BLM-induced increases of inflammatory cell counts, elevated levels of total protein and various inflammatory cytokines such as TNF-α, IL-1β and IL-6 in BALF were markedly reduced. Meanwhile, GCA treatment (100, 200 mg/kg bw/d) significantly inhibited BLM-induced elevation of myeloperoxidase (MPO; a marker of neutrophil influx and oxidative stress), MDA, TGF-β1, p-Smad2, p-Smad3, and mesenchymal cell markers (α-SMA, FN and vimentin), accompanied by down-regulation of AEC marker (E-cadherin) in the lungs ([@bib31]). *In vitro* by employing a murine fibroblast cell line 3T6, GCA could lead to the down-regulated expression of ECM degradation proteins (MMP-3, MMP-7, MMP-8 and MMP-9), anti-apoptotic protein Bcl-2 and cell cycle regulatory proteins (Cyclin B1, Cyclin D1 and Cyclin E) along with up-regulated pro-apoptotic protein Bax and G1 check-point proteins (P53 and P21), as well as the executors of apoptotic events (cleaved caspase-3, cleaved caspase-9 and cleaved poly ADP-ribose polymerase (PARP)) ([@bib31]). It also demonstrated that GCA significantly suppressed the migration and invasion of 3T6 cells by scratch wound assay and Transwell assay. It demonstrate that GCA owns the activity to ameliorate BLM-induced PF, inflammation, oxidative stress, EMT and activation of TGF-β signaling pathway, suppress the proliferation and migration of FB, and promote FB apoptosis.

Andrographolide (Andro), an active diterpenoid labdane component extracted from *Andrographis panicula*, is generally prescribed for treatment of inflammatory associated diseases, including asthma, laryngitis and upper respiratory tract infection ([@bib47]). It has shown that Andro sulfonate nebulization could improve the life quality scores, blood gas indexes and forced expiratory volume in one second (FEV1) percentage of predicted value in treating acute exacerbation of chronic obstructive pulmonary disease (COPD) patients ([@bib17]). A recent work has explored the enhanced anti-tumor activity and reduced toxicity by combination Andro and BLM in the established ascitic tumor-bearing mice model that induced by intraperitoneal injected with H22 hepatoma cells (2×10^6^ cells/mouse) ([@bib38]). The study indicated that BLM combined with Andro was significantly more effective than BLM alone on inhibiting the tumor growth, arresting the cell cycle at G0/G1 phase, promoting the capase-3 and -8 activity to induce cancer cell apoptosis, which may be related to the transcriptional regulation of P53/P21/Cyclin pathways. Moreover, BLM induced PF in tumor-bearing mice, but BLM combined with Andro dramatically alleviated the lesion in PF by activating the SOD, suppressing MDA and Hyp production, meanwhile, attenuating the IL-1β, TNF-α, IL-6 and TGF-β1 level ([@bib38]). These events were associated with the effect of Andro on the inhibition of protein expression of TGF-β1, α-SMA, p-Smad2/3, and enhanced expression of Smad7. Thus, Andro could improve BLM-based chemotherapy by both enhancing BLM tumoricidal effect and reducing BLM-associated side-effects, which maybe mediated by effecting cell cycle and apoptosis on tumor cells, and weakening the inflammation and collagen over-production in BLM-induced PF ([@bib38]). It renders that Andro might be a promising adjuvant therapeutic agent with the combination of BLM in cancer chemotherapy and worthy of further synergistic study in clinical.

3.3. Glycosides {#s0030}
---------------

Paeoniflorin, a monoterpene glucoside, is the main active constituent extracted from the dry roots of *Paeonia lactiflora* Pall., which is extensively used in China for more than 1000 years to treat numerous diseases including patients with terminal cancer ([@bib140]). In mice treated with BLM, paeoniflorin (50 mg/kg) significantly prolonged the survival periods, attenuated the inflammatory cells infiltration, interstitial fibrosis, and ECM deposition, decreased the contents of Hyp, Col-I and α-SMA as well as the expression of TGF-β1, Smad4 and p-Smad2/3 in lung tissues ([@bib48]). Moreover, paeoniflorin increased Smad7 expression and interferon (IFN)-γ content, but only slightly affected the mRNA expression of MMP-1 and TIMP-1 in lung tissue of mice. The therapeutic potential for the treatment of BLM-induced PF mainly by suppressing ECM deposition in lung tissue through reducing the synthesis of Col-I by inhibiting the activation of TGF-β/Smad pathway and increasing the expression of IFN-γ ([@bib48]). Recently, it was found that TGF-β1-induced EMT, shown by changed cell morphology, increased cell migration, up-regulated vimentin and α-SMA expression, and Col-I and Col-III levels with decreased E-cadherin expression, were repressed by the co-incubation with paeoniflorin in A549 cells ([@bib49]). Moreover, paeoniflorin could dose-dependently attenuate TGF-β1-induced expression of Snail (a major transcription factor governing EMT) and p-Smad2/3, markedly increased Smad7 level, but slightly affected the activation of p38 MAPK in A549 cells ([@bib49]). These results provide further evidence that paeoniflorin suppresses the early stages of TGF-β mediated EMT in AEC, likely by decreasing Snail expression *via* a Smad-dependent pathway. These data provide the laboratory evidence of paeoniflorin in treating patients with PF.

Naringin (4′,5,7-trihydroxy-flavonone-7-rhamnoglucoside) is a well-known flavanone glycoside with a strong oxygen radical scavenger by rapid donation of hydrogen atom to radicals ([@bib100]). The investigators had previously found the significant inverse associations between lung cancer risk and the main food sources of naringin (white grapefruit) after adjusting for smoking and intakes of saturated fat and beta-carotene ([@bib63]). In a mice model with paraquat (PQ, 50 mg/kg, *i.p*.)-induced acute lung injury (ALI) and PF, daily treatment with naringin increased the survival rates of mice within 7 days ([@bib18]). In addition, naringin treatment significantly reduced PQ (20 mg/kg, *i.p*.)-induced up-regulation of TNF-α, TGF-β1, MMP-9 and TIMP-1, levels of pulmonary MDA and Hyp, while increased the activities of enzymatic antioxidants including SOD, GSH-Px and HO-1, suggesting that it may be a potential therapeutics for management of PQ intoxication *via* alleviating oxidative stress, regulating TGF-β1 activity and MMP-9/TIMP-1 ratio, and reducing the collagen fibers deposition ([@bib18]). Turgut and coworkers recently published a work of naringin on BLM (5 mg/kg; *via* the tracheal cannula)-induced PF in rats ([@bib120]). The authors announced that naringin (80 mg/kg) administration led to a significant decrease in thin lined alveolar septa, inflammatory cell infiltration, Ashcroft quantitative pathological scoring, and mast cell recruitment compared with the BLM group; moreover, it markedly decreased the rats' lung index and increased body weight, reduced TNF-α and IL-1β activities, Hyp content, and MDA level, while increased GPx and SOD activities ([@bib120]). The protective effects of naringin on lung cancer patients and experimental PF may be due to its potential of preventing the formation of oxygen free radicals, reducing inflammatory cytokine levels, and/or removing them from the medium and also its antioxidant nature, which may also benefit human suffers.

Salidroside, isolated from *Rhodiola rosea* L., is a phenolic glycoside and has long been used as a medicinal herb to prevent high altitude sickness in China. It was seen that salidroside could protect against epirubicin-induced early left ventricular regional systolic dysfunction in patients with breast cancer ([@bib150]). Surprisingly, salidroside has also been reported to protect against PF in a recent work ([@bib116]). It was reported that salidroside attenuated BLM-triggered structure distortion, collagen overproduction, excessive inflammatory infiltration, and pro-inflammatory cytokine release, and oxidative stress damages in lung tissues ([@bib116]). In addition, salidroside inhibited the levels of p-IκBα, p-Smad2/3, TGF-β1, vimentin, FN, α-SMA, and nuclear factor kappa B (NF-κB) p65 nuclear accumulation, while up-regulated E-cadherin level and activated Nrf2-antioxidant signaling in BLM-treated lungs. Besides, salidroside was capable of reversing the recombinant TGF-β1-induced EMT-like changes in human A549 cells and primarily cultured rat AEC *in vitro* ([@bib116]). Collectively, salidroside may drive new drugs in protecting against fibrotic lung diseases. More studies are needed to confirm and increase the clinical application of these results.

Astragalin, kaempferol-3-O-glucoside from leaves of persimmon and green tea seeds, has been used to elucidate its effects on oxidative stress-induced airway epithelial BEAS-2B cells by H~2~O~2~ and OVA-sensitized BALB/c mice ([@bib20]). It reported that exposure of 20 μM H~2~O~2~ accelerated E-cadherin loss and vimentin induction, increased Col-I production in airway epithelial BEAS-2B cells, which was reversed by non-toxic astragalin. Astragalin also reduced the collagen fiber deposition, airway tissue levels of ROS and vimentin enhanced by OVA challenge ([@bib20]). Furthermore, astragalin blocked H~2~O~2~-induced expression of the autophagy-related beclin-1 and light chains 3 A/B (LC3A/B) in BEAS-2B cells and OVA-challenged airway subepithelium. Meanwhile, the induction of autophagy by spermidine influenced the epithelial induction of E-cadherin and vimentin that was blocked by treating astragalin. These results demonstrate that astragalin was effective in ameliorating oxidative stress-associated PF through disturbing airway EMT and epithelial autophagic stress. However, little is known about its role in clinical.

3.4. Phenols {#s0035}
------------

Resveratrol (Res), trans-3,5,4′-trihydroxystilbene, a natural plant polyphenol that mainly found in some plant species, has been proven to improve the lung functions of COPD patients and reduce inflammatory biomarkers in patients with nonalcoholic fatty liver disease ([@bib27], [@bib78]). The authors carried out a study using the first oral dose of Res (10 mg/kg) to the male Wistar albino rats just after 14 days of intratracheal BLM exposure and continued until sacrifice on 29th day ([@bib2]). The data showed that Res administration markedly decreased the counts of total cells and neutrophils in BALF, reduced the levels of Hyp (in lungs) and MDA (in lungs and serum), while increased the levels of T-AOC (in lungs and serum) when compared to BLM rats. However, Res could slight reduce the increment of fibrosis score that BLM triggered, although it was not reached at statistically significant level. This preclinical study indicated that the treatment of Res at a dose of 10 mg/kg when administered in the late post BLM period (14 days after BLM) suppressed, at least in part, the lung fibrosis induced by BLM exposure in rats ([@bib2]). Further study reported a role of Res (injected intraperitoneally at 0.3 mg/kg once daily) on LPS (a single intratracheal dose of 5 mg/kg)-induced changes of EMT and PF during a 28-days period in male ICR mice ([@bib156]). The authors found that 28 days with Res treatment not only markedly attenuated LPS-induced extensive deposition of fibrillar collagen and the destruction of normal pulmonary architecture, but also decreased TGF-β1 production, Smad2/Smad3 phosphorylation and Smad4 expression, and reversed EMT as evidenced by the increased E-cadherin and decreased α-SMA levels. Moreover, Res therapy for 28 days significantly attenuated the MDA level, increased the levels of T-AOC, CAT and SOD in lung tissue of LPS-evoked mice ([@bib156]). These data suggest that inhibition of TGF-β1/Smad activation and EMT may contribute to the protection against LPS-induced PF afforded by Res. Further clinical evidence is necessary to confirm its role in PF.

Curcumin, a natural phytochemical present in turmeric, has been shown to play a major role in various chronic diseases, including cardiovascular, pulmonary, autoimmune and neoplastic diseases ([@bib1]). It also showed that curcumin effectively inhibited the proliferation (1--20 μM curcumin) and collagen secretion (5, 10 μM curcumin in the absence or presence of 6 ng/ml TGF-β) of lung FB from PF patients in a dose-dependent manner ([@bib108]). Curcumin also boosted antioxidant defenses by increasing HO-1 levels in the isolated mouse pulmonary microvascular endothelial cells (PMVEC) and primary FB, and blocked radiation-induced generation of ROS ([@bib64]). In addition, the Hyp level in irradiated lungs was evidently lower, and the survival rate and HO-1 level in lungs were elevated in mice fed the 5% (w/w) curcumin diet, whereas curcumin supplementation did not affect tumor response to radiation. Moreover, 1% curcumin significantly decreased TNF-α level in BALF from LPS-challenged mice; the decrease was more pronounced when curcumin was given at a dose of 5% ([@bib64]). Using the model of reovirus 1/[L]{.smallcaps}-induced acute viral pneumonia which displays many characteristics of human acute respiratory distress syndrome (ARDS)/ALI, female CBA/J mice were treated with curcumin (50 mg/kg) 5 days prior to intranasal inoculation with 10^7^ PFU reovirus 1/L and daily, thereafter ([@bib5]). The study showed that curcumin treatment *in vivo* effected both inflammatory (diffuse alveolar damage) and fibrotic lesion development leading to a significant reduction in the development of ALI/ARDS in reovirus 1/[L]{.smallcaps}-infected mice, potentially *via* the modulation of cytokine/chemokine expression through the NF-κB pathway as well as the host fibrotic response during the regeneration phase of the disease through modulation of the TGF-β pathway ([@bib5]). In a clinical study directly on PF patients with paraquat poisoning, curcumin (oral, 1 g/kg day) in combination with conventional therapy could more significantly prolong the survival time of patients, reduce the levels of MMP-9 and TIMP-1, and attenuate the degree of PF than those of the only conventional therapy group, but cannot reduced the mortality rate ([@bib50]). These work indicate that curcumin may be an attractive new agent in the treatment of PF.

Epigallocatechin-3-gallate (EGCG), a kind of polyphenols of green tea, has been studied for its anti-oxidative ([@bib42]) and anti-fibrotic properties ([@bib111], [@bib112], [@bib113], [@bib146]). Upon EGCG (20 mg/kg) treatment, BLM-triggered increased level of Hyp and activities of pathophysiological enzymes such as aspartate transaminase, alanine transaminase, lactate dehydrogenase (LDH) and alkaline phosphatase were attenuated in Wistar rats ([@bib112]). BLM-induced rise in the level of glycoconjugates and activities of matrix degrading lysosomal enzymes in lungs and serum were reduced upon EGCG supplementation along with attenuated BLM-induced ultrastructural changes as observed from transmission electron microscopy studies ([@bib112]). Furthermore, the levels of ROS, lipid peroxide (LPO), histamine and serotonin, the activity of MPO, and the expression of NF-κB, TNF-α and IL-1β, were increased due to BLM challenge, however, they were significantly reduced on EGCG treatment ([@bib111]). It also showed increased inflammation and alveolar damage by histopathological analysis and accumulated collagen deposition by picrosirius red staining in BLM-challenged rats that were decreased upon EGCG treatment ([@bib111]). In addition, the declined activities of SOD, CAT, GSH, GST and NAD(P)H: quinone oxidoreductase 1 (NQO1) in BLM-injured rats were restored upon EGCG treatment ([@bib111]). EGCG also induced Nrf2 expression, but had no significant change on the expression of Kelch like ECH-associated protein (Keap)-1, a vital factor in Nrf2 signaling cascade. It indicates Nrf2-Keap1 signaling involves EGCG enhanced anti-oxidant activities and Phase II enzymes with subsequent restraint inflammation during BLM-induced PF ([@bib111]). Recently, Sriram and partners published additional data of the effects of EGCG focused on regulating FB activation and TGF-β1 signaling ([@bib113]). In the rat model, EGCG treatment normalized the BLM induced significant elevation of MMP-2 and -9 expression, increased RNA and protein expression of TGF-β1, Smads and α-SMA ([@bib113]). *In vitro*, simultaneous treatment of EGCG to FB (WI-38 cells) significantly decreased the increase of FB proliferation, Hyp level, and protein expression levels of p-Smad, α-SMA and Col-I, alongside normalizing the MMPs expression upon TGF-β1 incubation ([@bib113]). It revealed that EGCG inhibited FB activation and collagen accumulation by inhibiting TGF-β1 signaling and thus may be effective agent against PF. Not surprisingly, treatment with EGCG (intraperitoneally injection; 25 mg/kg) daily for 30 days also exerted protective role on irradiation-induced PF in rats using a dose of 22 Gy ([@bib146]). The study declared that EGCG treatment reduced irradiation-induced rat mortality rates and improved histological changes in the lung, lessened collagen depositions, MDA content, and serum levels of TGF-β1, IL-6, and IL-10, while activated Nrf-2, HO-1, and NQO-1 ([@bib146]). Lately, a phase II trial confirmed that EGCG (oral, 440 μmol/L) is effective and safe to treat acute radiation-induced esophagitis in patients with stage III lung cancer with depressed radiation therapy oncology group score and pain score ([@bib157]). Collectively, blockage of several key events in experimental lung fibrosis and the inhibitory role in lung cancer render EGCG as a promising anti-fibrotic agent for PF.

Corilagin, which is discovered in a number of medicinal plants such as *Caesalpinia coriaria,* has shown anti-fibrotic properties in treating PF ([@bib129]). It was shown to reduce the number of apoptotic lung cells and prevent lung epithelial cells from membrane breakdown, effluence of lamellar bodies and thickening of the respiratory membrane through a transmission electron microscopy 24 h after aerosol BLM (1 mg/ml) exposure ([@bib129]). Moreover, BLM-triggered expression of MDA, IKKα, p-IKKα, NF-κB P65, TNF-α and IL-1β, and reduced expression of I-κB in mice lung tissue or in BALF, were reversed by high-dose corilagin (100 mg/kg *i.p*) more dramatically than by low dose (10 mg/kg *i.p*). Corilagin also inhibited TGF-β1 production and α-SMA expression in lung tissue. This finding provides evidence that corilagin attenuates lung injury and fibrosis as a consequence of BLM inhalation, which is attributed to its anti-oxidative, anti-inflammatory activities, as well as inhibition of NF-κB and TGF-β1 signaling ([@bib129]). Corilagin may be a promising anti-fibrotic agent but warrants further studies.

Gallic acid (GA; 3,4,5-trihydroxybenzoic acid) and its derivatives are considered the main polyphenolic compounds in areca nut, green tea, walnut, *etc*. Preclinical studies have shown that GA possesses different pharmacological effects including anti-oxidant, antiapoptotic ([@bib109]). In a PF model, the rats were given GA orally at doses (50, 100, and 200 mg/kg/day) for 28 consecutive days started 7 days before the administration of single intratracheal instillation of BLM ([@bib87]). The results showed that oral administration of GA significantly reversed the increase of inflammatory or fibrotic changes, collagen content, levels of MDA, and pro-inflammatory cytokines such as TNF-α and IL-1β, and the decrease of non-enzymatic (total thiol) and enzymatic (GPx) antioxidant contents in the rats' lung tissue induced by BLM. Thus, the supplement with GA as an adjuvant therapy in fibrotic lung disease may be a promising compound in reducing the side effects of BLM ([@bib87]). Therefore, further data *in vivo* and in clinical are indispensable to confirm its role in this area.

Salvianolic acids, the main active water-soluble extracts of *Salvia miltiorrhiza* Bunge (commonly known as 'Danshen'), have a remarkable curative effect on patients of silicosis combined with cor pulmonale ([@bib125]), the principle poly-phenolic acids of which include salvianolic acid A (SAA) and SAB. BLM (5 mg/kg; intratracheal injection)-treated rats exhibited increased alveolar wall thickness and collagen deposition in lung tissues, but these were greatly attenuated by daily tail-vein injection of SAA (2.5, 5, and 10 mg/kg) ([@bib91]). In the *in vitro* work, SAA significantly inhibited the proliferation, adhesion and migration of a stable cell line of murine 3T6 embryonic FB, partly due to its strong induction of cell cycle arrest and apoptosis. Consistently, the decreased expression of the cell cycle-related proteins cyclin D1, cyclin E1, and cyclin B1, and increased expression of p53 and p21 were observed in SAA-treated cells. In addition, the anti-apoptotic Bcl-2 protein decreased in a dose-dependent manner, while cleaved caspase-3 protein increased upon SAA treatment ([@bib91]). However, it lacks the evidence whether SAA might reverse the symptoms of the late stage of established *in vivo* PF model. A recent work has showed the antiplatelet efficiency of SAB in acute coronary syndrome patients undergoing treatment with clopidogrel plus aspirin ([@bib77]). In another work, the treatment with only SAB did not affect the proliferation and differentiation of human MRC-5 embryonic lung FB ([@bib154]). Interestingly, SAB (1 or 10 μmol/l) significantly inhibited TGF-β1-induced cell proliferation, Col-I expression, endogenous TGF-β1 production, and α-SMA expression in lung FB. Moreover, the inhibitory effect of SAB on TGF-β1-induced proliferation and differentiation in lung FB was more significant when treated with high-dose SAB ([@bib154]). Nevertheless, further investigations are required to explore the anti-fibrotic role of SAB in animal models and patients with PF.

3.5. Alkaloids {#s0040}
--------------

Neferine is a bisbenzylisoquinline alkaloid which has proved to inhibit platelet aggregation in patients with hyperlipidemias ([@bib106]). Recent work showed that neferine treatment (20 mg/kg, oral, b.i.d) showed less inflammation and fibrosis, suppressed the increased content of Hyp, and levels of MDA, MPO, TNF-α, IL-6 and endothelin-1 (in lung tissue or in plasma), while reversed the decreased SOD activity that triggered by intratracheal BLM administration in mice ([@bib158]). Additionally, neferine blocked BLM-induced increase of NF-κB in nuclear extracts and TGF-β1 in total protein extracts of murine RAW264.7 macrophages. The beneficial effect of neferine might be associated with its activities of anti-inflammation, anti-oxidation and cytokine inhibition ([@bib158]). Besides, further study showed the effects of neferine (20 mg/kg, oral, b.i.d) after the third amiodarone instillation on a mouse PF model which was developed through intratracheal instillation of amiodarone (6.25 mg/kg) on the 1st, 3rd and 5th day ([@bib88]). This work declared that neferine significantly restored the significant reductions in body weights, the increased levels of lung index and Hyp, the abnormal histological findings, the serum surfactant protein-D (SP-D) increase, the Th1/Th2 imbalance by decreasing IL-4 and increasing IFN-γ levels and the increase in the population of CD4^+^CD25^+^ Tregs associated with amiodarone instillation in mice ([@bib88]). These results at least indicated the beneficial effect of neferine on the patients treated with BLM or amiodarone by alleviating above undesirable outcomes.

Isoliensinine, a bisbenzylisoquinoline alkaloid extracted from the seed embryo of *Nelumbo nucifera* Gaertn., which served as "heat-clearing drugs", has been considered to prevent BLM-induced PF in mice ([@bib137]). Isoliensinine (10, 20, 40 mg/kg; oral, tid) was administered for 14 days after intratracheal treatment with a single dose of BLM while the control group was instead of intratracheal saline. Administration of isoliensinine not only remarkably suppressed the increased Hyp content in the lungs, abated the lung histological injury, but also reversed the up-regulated MDA level and enhanced the SOD activity in the lungs and serum induced by BLM in a concentration-dependent manner ([@bib137]). Moreover, isoliensinine also significantly inhibited the over-expression of TNF-α and TGF-β1 induced by BLM. These results shed light on the inhibitory effect of isoliensinine on BLM-induced PF, but further evidence is necessary to investigate its role on PF *in vitro* ([@bib137]). Whereas, the related effects of this compound on patients with PF or other lung diseases need to be uncovered.

Corydalis *yanhusuo* and its active ingredients tetrahydropalmatine (THP) have curative effect on senile chronic bronchitis in patients ([@bib15]) and irradiation-induced lung injuries in rats, respectively ([@bib148]). It was reported that pretreated with THP decreased lung injury by inhibiting the lung cells apoptosis as evidenced by decreased levels of apoptotic mediators (cytochrome c and caspase-3), suppressed lung inflammation by decreasing BALF cells recruitment and inflammatory cytokines levels (TNF-α, IL-6, and TGF-β1), reduced PF by lowering Hyp content and MDA level in comparison to those irradiated alone ([@bib148]). Moreover, the THP combined with IR group, had comparatively integrity pulmonary alveoli structure, less infiltration of inflammatory cells and unapparent alveolar septa thickening. These data indicate the potential role of THP in attenuating lung injury and fibrosis. However, further studies on the role of Corydalis *yanhusuo* and THP in alleviating PF are necessary. Due to its involvement in possessing multiple biologic activities, THP may act the anti-fibrotic effects through other unknown mechanisms.

Oxymatrine (OM) is a bioactive alkaloid constituent derived from *Sophora flavescens* Ait. (kurorinone, Kushen in Chinese) that has been approved by the State Food and Drug Administration of China for treating hepatitis B ([@bib128]). [@bib76]) demonstrated the anti-fibrotic therapeutic benefit treated with daily OM (10, 20 or 40 mg/kg) one day after endotracheally instilled with BLM for 21 days in mice. In this study, OM improved BLM-induced lung pathological changes, reduced MPO activity and MDA levels, inhibited the release of TNF-α and IL-6, decreased the expression of iNOS in lung tissues and thus prevented NO release in response to BLM challenge in a dose-dependent manner ([@bib76]). In addition, OM decreased the expression of TGF-β1, p-Smad2 and p-Smad3 in the lungs. It indicated that OM could attenuate BLM-induced PF in mice *via* the inhibition of pro-inflammatory cytokine expression and the TGF-β/Smad pathway. Besides, OM prevented NO over-production through reducing iNOS expression in mouse lungs ([@bib76]). These results suggest that OM may be a promising candidate for the prevention of lung damage or interstitial PF. However, the precise mechanism whereby OM inhibits iNOS expression and the protective role of OM on the established PF model or PF patients, should be clarified.

3.6. Other single component from herbs {#s0045}
--------------------------------------

A recent study has confirmed that osthole (7-methoxy-8-isopentenoxycoumarin), a natural coumarin, appears to confer a protective effect in PF. The PF mode rats were induced by instilled intratracheally BLM and then subsequently administered osthole (40 mg/kg; the first dose was after instilling BLM for 1 h) by gavage daily until four weeks ([@bib39]). The authors found that osthole treatment attenuated BLM-induced PF changes and diffused lung inflammation, significantly decreased the body weight loss, lung index and the expression of the inflammatory mediators (IL-6, TNF-α, IL-1β), ANG II and TGF-β1, and reversed ACE-2 and ANG-(1--7) production in rat lungs ([@bib39]). It indicates that osthole exerts beneficial effects on BLM-induced rat PF, which perhaps *via* modulating the ACE-2/ANG-(1--7) axis and inhibiting lung inflammation.

Gamboge is a dried yellow resin secreted by *Garcinia hanburyi* Hook.f. \[Clusiaceae (Guttiferae)\] in Southeast Asia, while gambogic acid (GBA) is the main active compound. It demonstrated that GBA prevented TGF-β1 stimulated EMT with a decrease in vimentin and p-Smad3, and an increase in E-cadherin in A549 AEC, while suppressed endothelial-mesenchymal transition (EndoMT) with a decrease in vimentin and an increase in VE-cadherin in human pulmonary microvascular endothelial cells (HPMECs), respectively ([@bib98]). Moreover, GBA treatment inhibited TGF-β1 and CoCl~2~ stimulated human lung fibroblasts (HLF)-1 proliferation with reduction of platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF)-2, and ameliorated BLM-induced PF with a lower rate of Vasohibin-2 (VASH-2; an endogenous and vascular endothelial growth factor (VEGF)-independent angiogenic factor)/VASH-1 (a unique endogenous angiogenesis inhibitor) at early stage of fibrosis, and reduction of the pathological score, collagen deposition, as well as the expression of α-SMA, PDGF and FGF-2 at fibrotic stage ([@bib98]). Previously, a phaseⅠhuman tolerability trial of GBA showed that its maximal tolerated dose and dose-limiting toxicity is involved with liver dysfunction and pain in cancer patients, and thus further work to investigate its anti-fibrotic effect in clinical should consider these key factors ([@bib164]).

4. Volatile oil from herbs for the therapy of PF {#s0050}
================================================

4.1. Volatile extract of Houttuynia cordata Thunb {#s0055}
-------------------------------------------------

*Houttuynia cordata* Thunb. (HC) had been previously evaluated owning the activities to resist severe acute respiratory syndrome (SARS) in patients, due to its role in decreasing patients mortality rate and improving arthralgia, myalgia as well as arterial oxyhemoglobin saturation ([@bib71]). HC volatile extract was applied to a LPS-induced rapid pulmonary fibrosis (RPF) rat model and analyzed its effect on ALI and RPF ([@bib26]) ( [Table 2](#t0010){ref-type="table"}). The active ingredients of the HC vapor extract included 4-terpineol, α-terpineol, [L]{.smallcaps}-bornyl acetate and methyl-*n*-nonyl ketone by gas chromatograph-mass spectrometer (GC-MS) ([@bib26]). *In vitro*, HC vapor extract could inhibit the viability of RAW264.7 and NIH/3T3 cells, and dose-dependently decreased the expression of TGF-β1 and enhanced the expression of IFN-γ in NIH/3T3 embryonic FB ([@bib26]). In addition, α-terpineol enhanced IFN-γ expression in NIH/3T3 embryonic FB and inhibited the growth of RAW 264.7 macrophages, while [L]{.smallcaps}-bornyl acetate presented the opposite effects, but both of them inhibited the growth of NIH/3T3 in a dose-dependent manner. In LPS-induced rat RPF, HC vapor extract treatment evidently up-regulated the ratio of lymphocytes and mononuclear phagocytes at the 7th day, reduced the expression of TGF-β1 and Smad2/3, the content of lung Hyp (16.5 mg/kg) and serum LDH, and increased the expression of IFN-γ and Smad7 ([@bib26]). Current investigation shows that the pharmacologically active ingredients of HC vapor extract might be α-terpineol and [L]{.smallcaps}-bornyl acetate, which reduced ALI and RPF, while IFN-γ and the TGF-β1/Smad pathway might be the pharmacological targets of HC. Considering a fact that the final development of SARS symptom is similar to that of PF, digging the role of HC or its vapor monomers in PF would be more attractive.Table 2The studies of volatile oil from herbs for the therapy of PF.Table 2**Volatile oilHerbsDetectionObjects (model inducers, doses)EffectsRef.*****In vitro****In vivo*****PF patients**HC*Houttuynia cordata* Thunb.------SARS patientsMortality rate ↓, life quality ↑[@bib71]GC-MSRAW264.7 macrophages, NIH/3T3 embryonic FB (LPS, 100 ng/ml)Wistar rats (LPS, 3 mg/kg)--TGF-β1/Smads signal ↓, IFN-γ ↑[@bib26]α-terpineol------IFN-γ ↑, NIH/3T3 FB ↓[L]{.smallcaps}-bornyl acetate------IFN-γ ↓, NIH/3T3 FB ↓NS volatile oil*Nigella sativa* L.----Wistar albino rats (hydrochloric acid, 2 ml/kg)--iNOS ↓, SP-D ↑[@bib54]Allicin*Allium sativum* L.----SD rats (CP, 150 mg/kg)--LDH ↓, TNF-α ↓, reduced GSH ↑[@bib4][^2]

4.2. Volatile oil of Nigella sativa L {#s0060}
-------------------------------------

The black seeds of *Nigella sativa* L. (NS), contain \>30% of fixed oil and 0.4--0.45% wt/wt of volatile oil (thymoquinone, p-cymene, a-piene, *etc*.), and have beneficial effects on asthma and dyspnea, digestive and gynecology disorders ([@bib34]; [@bib54]; [@bib56]). In the study, the saline, Pulmocare (a specialized nutritional supplement given to pulmonary patients) and hydrochloric acid were injected into the rats' lungs in a volume of 2 ml/kg to develop experimental lung injury, and then the rats received daily oral doses of NS volatile oil (400 mg/kg body weight) by means of intragastric intubation for 7 days starting immediately after the lung aspiration of these materials ([@bib54]) ([Table 2](#t0010){ref-type="table"}). The results showed that NS volatile oil treatment inhibited the inflammatory lung responses, evidently reduced the peribronchial inflammatory cell infiltration, alveolar septal infiltration, alveolar edema, alveolar exudate, alveolar macrophages, interstitial fibrosis, granuloma and necrosis formation, with a significant reduction in the activity of iNOS and a rise in SP-D, (a mediator of innate host defense and inflammation) in different lung aspiration models ([@bib54]). Later, Boskabady and colleagues completed a study in asthmatic patients, which showed that treatment with the boiled extract of NS could increase the suffers' lung function ([@bib10]). These results indicate that NS volatile oil might be beneficial in lung interstitial fibrosis with potential therapeutic properties in a clinical setting.

4.3. Allicin {#s0065}
------------

Allicin (diallylthiosulphinate), one of the active compounds of freshly crushed garlic (*Allium sativum* L.), possesses a variety of biological activities such as antimicrobial, anti-inflammatory, anti-thrombotic, anti-atherosclerotic, serum lipid lowering and anticancer activities ([@bib104]). The injury of normal tissues is the major limitation of using cyclophosphamide (CP), a cytotoxic alkylating agent that has been widely used in the treatment of various neoplastic diseases and autoimmune disorders. Meanwhile, lack of detoxifying enzymes, aldehyde oxidase and aldehyde dehydrogenase in the lungs is a cause of selective CP toxicity to lung tissue. Ashry and colleagues carried out a study to assess whether allicin (50 mg/kg/d, p.o.) can ameliorate CP (150 mg/kg, *i.p*.)-induced early lung injury in male SD rats ([@bib4]) ([Table 2](#t0010){ref-type="table"}). It showed that a single intraperitoneal pretreatment of rats daily with oral allicin seven days prior to and seven days after CP injection effectively blunted CP-induced histopathological changes, significantly reduced the increase of lung index and serum levels of total protein, LDH and TNF-α, and reversed the decrease of total reduced GSH level with increased survival rate of the rats ([@bib4]). The results indicate that allicin may partially protects healthy lung against CP injury. Recent work provided evidence that allicin could improve the burning sensation, mouth opening, and oral health-related quality of life in these stage II oral submucous fibrosis patients ([@bib52]). It further encourages the special work of allicin on the fibrotic lung disease.

5. Multiple components from single herbs for the therapy of PF {#s0070}
==============================================================

5.1. Safflor yellow {#s0075}
-------------------

SY (Safflor yellow) is the effective part of the aqueous extract of *Carthamus tinctorius* L.. The authors investigated the effects of SY (intraperitoneal, 25, 50 mg/kg/d) on the rats of PF induced by BLM (consecutively for four weeks) and on differentiation of HELFs into MFb stimulated by TGF-β1 ([@bib124]). The data showed that SY alleviated the loss of body weight, the increase of lung Hyp content, α-SMA positive cells, and TGF-β1 expression, as well as the pathologic changes of PF caused by BLM instillation. Furthermore, suitable concentrations of SY inhibited α-SMA expression during TGF-β1-stimulated differentiation of lung FB into MFb ([@bib124]). In a study of 70 PF patients that treated with methylprednisolone (oral, 0.4 mg/kg daily) or a combined drugs (SY sodium chloride injection (100 ml daily, containing 80 mg SY) and methylprednisolone (oral, 0.4 mg/kg daily)), the authors observed that the scores of cough, dyspnea, cyanosis, rales and total score of the combined drugs treatment group were significantly lower than those of methylprednisolone group ([@bib114]). Moreover, the FEV1/(forced vital capacity, FVC) was significantly higher than those in the methylprednisolone group, while the serum levels of hyaluronic acid, laminin, procollagen III, Col-III and blood urea nitrogen were significantly lower than those in the single drug treatment group ([@bib114]). It may provide direct evidence of SY application in PF patients.

5.2. Triterpene acids of Eriobotrya japonica (Thunb.) Lindl {#s0080}
-----------------------------------------------------------

It was found that triterpene acids of *Eriobotrya japonica* (Thunb.) Lindl. leaf (TAL), which were analyzed by HPLC containing ursolic acid, oleanolic acid, *etc*., could reduce BLM-induced alveolar structure destruction and collagen expression in rats ([@bib145]). Additionally, TAL decreased the expression of TNF-α and TGF-β1 in the culture supernatant of AMs that obtained from the BALF of BLM-induced rats. Recent data showed that Eriobotrya japonica (Thunb.) Lindl. leaf drink was demonstrated to obviously alleviate the gastrointestinal side effects of chemotherapy and improved the living quality of middle-late stage lung cancer patients ([@bib74]). However, no evidence shows whether loquat, TAL or the herb derivatives have improved effects on PF suffers.

5.3. Boswellic acids {#s0085}
--------------------

Boswellic acids (BA) are found in the gum resin of *Boswellia serrata* Roxb. ex Colebr. in parts of China and India. In the treatment of gonarthrosis, BA was shown to significantly reduce the patients' need for anti-inflammatory drugs ([@bib90]). While in the study of PF, BA (1 g/kg) reduced the number of infiltrating cells, ameliorated the destruction of lung architecture and attenuated BLM-induced PF in rats. Additionally, BA-treated rats had reduced number of macrophages, neutrophils in BALF, significantly lowered content of LDH and LPO in serum, and reduced levels of Hyp, TGF-β1, TNF-α, and 5-lipooxygenase (5-LOX) in lung tissue ([@bib3]). In contrast, the reduction of the activities of antioxidant events (SOD, GSH, CAT) in the blood and lung homogenate of the fibrotic rat were evidently reversed with BA treatment. This work suggests the prevention of BA on lung injury and fibrosis in rats, but it is unclear of its role in PF patients.

5.4. Rhodiola rosea L {#s0090}
---------------------

In a performed study in 40 cases of PF patients, Dazhu Hongjingtian (*Rhodiola rosea* L.) injection (Tonghua Yusheng Medicine Co., Ltd., China, 10 ml daily) in combination with conventional therapy of oral prednisone could significantly increase the patients' partial pressure of oxygen, maximum amount of pulmonary ventilation, pulmonary diffusion and total efficacy, but obviously decrease the symptom scores, which were better than those in the only conventional therapy of oral prednisone ([@bib142]). However, the patient sample is not enough to clarify its clinical benefits. The studies to investigate its possible side effects on the *in vivo* models should be considered first if further clinical trials were conducted.

5.5. Hirsutella sinensis mycelium {#s0095}
---------------------------------

*Hirsutella sinensis* mycelium (HSM), the anamorph of *Cordyceps sinensis*, a parasitic fungus that infects larvae of ghost moths, is a TCM that has emerged as an attractive substitute for the preparation of health supplements ([@bib93]). In a performed clinical study, Cordyceps sinensis extract-bailing capsule dosage (60 mg/(kg day)) in combination with methylprednisolone more obviously improved the total clinical cure rate, the arterial blood gas analysis and percentage of predicted FVC than patients receiving only methylprednisolone in PF patients ([@bib72]). Notably, a recent study provided the experimental evidence that HSM ethanol extract attenuates lung inflammation and fibrosis ([@bib45]). *In vitro*, the pretreatment with HSM inhibited TGF-β1-induced FN, α-SMA, p-Smad2/3 and p-Akt expression, and restored SOD expression in MRC-5 lung FB, while inhibited ROS production in mouse MLE12 lung epithelial cells ([@bib45]). Furthermore, HSM improved BLM-induced histopathological changes with decreased alveolar wall thickness, inflammatory cell infiltration, vascular congestion, and alveolar space collapse, accompanied by reduced collagen deposition and Ashcroft score, reversed total cell and leukocyte accumulation in BALF, attenuated the expression of IL-1β, IL-18, TGF-β1, Col-3α1, α-SMA, NOD-like receptor (NLRP)-3, P2×~7~R (a purinergic receptor that activates NLRP3 inflammasome), and caspase-1 activation in the lungs of BLM-treated mice ([@bib45]). These data suggest that *Cordyceps sinensis* and HSM may be promising materials in protecting against PF.

6. TCM formulations and their extracts for the therapy of PF {#s0100}
============================================================

Due to numerous clinical practice, it is well recognized that TCM formulations could be more effective than an isolated single constituent for disease management. The past years have witnessed a number of studies investigating the benefits of the TCM formulations and their active agents for the treatment of PF ( [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}). These formulas detail can be obtained from [Table 3](#t0015){ref-type="table"}, whereas the composition of some formulas was not fully showed because the TCM prescription may add few other herbs based on the special patients or not, especially in some work in Chinese.Table 3The herbal sources of TCM formulations and their extracts in the PF studies.Table 3**AgentsHerbal sources (ratio)Ref.**Renshen pingfei decoction*Panax ginseng* C.A.Mey., *Asparagus cochinchinensis* (Lour.) Merr., *Morus alba* L., *Lycium chinense* Mill., *Glycyrrhiza uralensis* Fisch., *Anemarrhena asphodeloides* Bunge, *Citrus reticulata* Blanco (1:1:1:1:1:1:1)[@bib16]Hu-qi-yin*Polygonum cuspidatum* Sieb. et Zucc., *Astragalus memebranaceus* (Fisch.) Beg. var. *mongholicus* (Beg.) Hsiao, *Salvia miltiorrhiza* Beg., *Ligusticum chuanxiong* Hort, *Angelica sinensis* (Oliv.) Diels, *Citrus reticulata* Blanco, *Glycyrrhiza uralensis* Fisch. (the per centum is 13%: 26%: 26%: 13%: 9%: 9%: 4%)[@bib161]Runfei decoction*Seeds of Prunus davidiana* (Carr.) Franch*., Glycyrrhiza glabra* L.*, Platycodon grandiflorus* (Jacq.) A.DC*., Ephedra equisetina* Bunge*, Prunus armeniaca* L.*, Lycium chinense* Mill.*, Morus alba* L.*, Inula japonica* Thunb.*, Lilium brownii* F.E.Br. ex Miellez*, Adenophora stricta* Miq.*, Paeonia lactiflora* Pall.*,* CaSO~4~·2H~2~O (10 g: 10 g: 10 g: 10 g: 10 g: 10 g: 12 g: 15 g: 20 g: 30 g: 30 g: 30 g)[@bib80]Shenlong decoction*Astragalus mongholicus* Bunge*, Adenophora stricta* Miq*., Rehmannia glutinosa* (Gaertn.) DC*., Pheretima aspergillum* (E. Perrier)*, Angelica sinensis* (Oliv.) Diels*, Ligusticum striatum* DC*., Glycyrrhiza glabra* L. (25 g: 30 g: 10 g: 10 g: 15 g: 15 g: 10 g)[@bib79]Qingre Huoxue Sanjie formula*Scutellaria baicalensis* Georgi*, Forsythia suspensa* (Thunb.) Vahl*, Paeonia suffruticosa* Andr., *Paeonia veitchii* Lynch*, Iphigenia indica* Kunth*, Prunella vulgaris* L., *etc*. (12 g: 12 g: 10 g: 10 g: 15 g: 15 g)[@bib119]DSQRL decoction*Panax ginseng* C.A.Mey*., Astragalus mongholicus Bunge*, *Ophiopogon japonicus* (Thunb.) Ker Gawl., *Angelica sinensis* (Oliv.) Diels, *Salvia miltiorrhiza* Bunge, *Ligusticum striatum* DC. (15 g: 30 g: 15 g: 10 g: 15 g: 15 g)[@bib152], [@bib153]Huqi Huoxue decoction*Reynoutria japonica* Houtt..*, Astragalus mongholicus* Bunge*, Salvia miltiorrhiza* Bunge*, Ligusticum striatum* DC*., Angelica sinensis* (Oliv.) Diels, *Citrus reticulata* Blanco*, Glycyrrhiza uralensis* Fisch.*, etc.* (unprovided ratio)[@bib149]Huaxian formula*Bupleurum chinense* DC.*, Scutellaria baicalensis* Georgi*, Codonopsis pilosula* (Franch.) Nannf.*, Pinellia ternata* (Thunb) Makino*, Trichosanthes kirilowii* Maxim*., Cinnamomum cassia* (L.) J.Presl*, Schisandra chinensis (*Turcz.) Baill.*, Zingiber officinale* Roscoe*, Trichosanthes kirilowii* Maxim.*, Cyperus rotundus* L*., Glycyrrhiza glabra* L*., Fritillaria thunbergii* Miq*., Ophiopogon japonicus* (Thunb.) Ker Gawl. (24 g: 9 g: 15 g: 12 g: 12 g: 12 g: 15 g: 6 g: 15 g: 12 g: 6 g: 12 g: 15 g)[@bib19]mKG formula*Angelica sinensis* (Oliv.) Diels., *Sophora flavescens* Aiton, *Glycyrrhiza uralensis* Fisch. (160 g: 60 g: 60 g)[@bib33]TJ-19 formula*Pinellia ternata* (Thunb.) Makino*, Glycyrrhiza glabra* L*, Cinnamomum verum* J.Presl*, Schisandra chinensis* (Turcz.) Baill.*, Erigeron breviscapus* (Vaniot) Hand.-Mazz*., Paeonia lactiflora* Pall.*, Ephedra sinica* Stapf*, Zingiber officinale* Roscoe (9 g of each ingredient)[@bib141]TQABDA method*Astragalus mongholicus* Bunge*, Curcuma phaeocaulis* Val*., Salvia miltiorrhiza* Bge*., Angelica sinensis* (Oliv.) Diels*, Fritillaria cirrhosa* D.Don*, Scutellaria baicalensis* Georgi*, Curcuma aromatica* Salisb*., etc.* (20 g: 10 g: 20 g: 15 g: 10 g: 10 g: 10 g)[@bib115]Bufei Huoxue decoction*Astragalus mongholicus* Bunge*, Codonopsis pilosula* (Franch.) Nannf*., Carthamus tinctorius* L*., Fritillaria thunbergii* Miq*., Salvia miltiorrhiza* Bge*., Ligusticum chuanxiong, Angelica sinensis* (Oliv.) Diels*, Lilium brownii* F.E.Br. ex Miellez*, Ginkgo biloba* L*., Citrus aurantium* L*., Perilla frutescens (*L.) Britt.*, Allium macrostemon* Bunge.*, etc.* (30 g: 20 g: 10 g: 15 g: 30 g: 10 g: 10 g: 10 g: 10 g: 10 g: 10 g: 10 g)[@bib136]Qingjin decoction*Astragalus mongholicus* Bunge*, Pseudostellaria heterophylla* (Miq.)Pax*., Cornus officinalis* Siebold & Zucc*., Epimedium sagittatum* (Siebold & Zucc.) Maxim*., Pheretima aspergillum* (E. Perrier)*, Prunus davidiana* (Carr.)Franch*., Paeonia lactiflora* Pall.*, Ligusticum striatum* DC.*, Buthus martensii* Karsch*, Hirudo nipponica* Whitman*, Smilacis* Glabrae*, etc.* (30 g: 30 g: 15 g: 15 g: 15 g: 15 g: 30 g: 15 g: 15 g: 8 g: 15 g)[@bib134]Yangyin Yiqi formula*Codonopsis pilosula* (Franch.) Nannf*., Ophiopogon japonicus* (Linn. f.) Ker-Gawl*., Lilium brownii* F.E.Br. ex Miellez*, Rehmannia glutinosa* (Gaertn.) DC., *Pinellia ternata* (Thunb.) Makino*, Glehnia littoralis* F.Schmidt ex Miq*., Fritillaria przewalskii* Maxim. ex Batalin.*, Polygonatum odoratum* (Mill.) Druce*, Atractylodes macrocephala* Koidz*., Astragalus mongholicus* Bunge*, Platycodon grandiflorus* (Jacq.) A.DC.*, Aster tataricus* L.f.*, Bambusa tuldoides* Munro*, Schisandra chinensis* (Turcz.) Baill. (20 g: 20 g: 20 g: 20 g: 10 g: 10 g: 10 g: 10 g: 15 g: 15 g: 15 g: 15 g: 15 g: 15 g)[@bib122]Jade Screen Powder*Astragalus mongholicus* Bunge*, Saposhnikovia divaricata* (Turcz.) Schischk*., Stephania tetrandra* S.Moore*, Platycodon grandiflorus* (Jacq.) A.DC*, Lonicera japonica* Thunb.*, Mentha spicata* L.*, Schisandra chinensis* (Turcz.) Baill.*, etc.* (40 g: 10 g: 15 g: 15 g: 12 g: 12 g: 15 g)[@bib144]YPF-G*Astragalus mongholicus* Bunge, *Atractylodes macrocephala* Koidz., *Saposhnikovia divaricata* (Turcz.) Schischk. (the ratio is 3:1:1)[@bib66][@bib22]YPF-P[@bib139]DBTG*Astragalus mongholicus* Bunge,[@bib30], [@bib28] and [@bib159]*Angelica sinensis*.(Oliv.) Diels (the ratio is 5:1)[^3]Table 4The benefits of TCM formulations and their extracts for the therapy of PF.Table 4**AgentsDetectionSample (inducer)ActionsRef.*****In vivo*****Patients**Renshen pingfei decoctionUPLC-QTOF-MSSD rats (BLM)--TGF-β1/Smads signal ↓, NF-κBl ↓, oxidative stress ↓[@bib16]Hu-qi-yin--SD rats (BLM)--Hyp ↓, TGF-β1 ↓[@bib161]Runfei decoction----Lung cancer patients (Thoracic radiotherapy)Radioactive PF incidence ↓, TGF-β ↓, IL-6 ↓[@bib80]Shenlong decoction--Wistar rats (BLM)--MMP-2/TIMP-1 imbalance ↓[@bib79]Qingre Huoxue Sanjie formula----Lung cancer, esophageal cancer or thymoma patients (Chest radiotherapy)Radioactive PF incidence ↓, life quality ↑, TGF-β1 ↓, IL-6 ↓, TNF-α ↓[@bib119]DSQRL decoction--SD rats (CCl4)--TGF-β1 ↓[@bib152], [@bib153]Huqi Huoxue decoction----PF patientsCurative effect ↑, adverse reaction ↓, treatment cost ↓[@bib149]Huaxian formula----Radiation-induced PF patientsMovement limitation ↓, disease impaction ↓, pulmonary function ↑[@bib19]mKG formulaUPLC-MS/MS and GC-MSBALB/c mice (BLM)--Collagen ↓, inflammation ↓, TGF-β1 ↓, α-SMA ↓[@bib33]TJ-19 formulaThree-Dimensional HPLCSD rats (BLM)--Hyp ↓, MDA ↓[@bib141]TQABDA method--PF patientsAlveoli ↓, TGF-β1 ↓[@bib115]Bufei Huoxue decoction----PF patientsEffective rate ↑, PaO~2~ ↑, total lung capacity ↑, CO diffusion capacity ↑, symptomatic score ↓, PaCO~2~ ↓[@bib136]Qingjin decoction----PF patientsLung function ↑, PaO~2~ ↑, hypoxia ↓, PaCO~2~ ↓[@bib134]Yangyin Yiqi formula----PF patientsTotal effective rate ↑, FEV1 ↑, FEV1/FVC(%) ↑, TGF-β1 ↓[@bib122]Jade Screen Powder----PF patientsCurative effect ↑, Karnofsky scores ↑, FEV1 ↑, FVC ↑, FEV1/FVC ↑, TGF-β1 ↓[@bib144]YPF-GHPLC-ELSDSD rats (BLM)--ECM ↓, TGF-β1 ↓, HMGB1 ↓, EMT ↓[@bib66][@bib22]YPF-PHPLC-GPCSD rats (BLM)--ECM ↓, TGF-β1 ↓[@bib139]Total glucosides of Danggui-Buxue-TangHPLC-ELSDSD rats (BLM)--ECM ↓, TNF-α ↓, MMP-9/TIMP-1 imbalance ↓, TGF-β1 ↓, α-SMA ↓, oxidative stress ↓[@bib30], [@bib28][@bib159][^4]

[@bib16]) detected 43 peak signals of the chemical components of Renshen pingfei decoction (RPFS) including mangiferin, caffeic acid, liquiritin, naringin, notoginsenoside R1, ginsenoside Rg1, *etc*. by UPLC-QTOF-MS analyses and evaluated the protective role of RPFS (6.5 g/kg daily) in a rat model of PF induced with BLM (5 mg/kg). RPFS exerted significant effects on PF model rats in improving lung function and decreasing Hyp content of lung tissue, reducing the levels of TGF-β1 and NF-κB in BALF, SOD and MDA levels in serum, as well as down-regulating TGF-β1 and Smad3 mRNA and protein expression of lung tissue compared with model group (only BLM injection) ([@bib16]). It suggests that RPFS has protective role on experimental PF, which might mediated by down-regulating TGF-β1/Smad3 signaling pathway. However, the role of the chemical components identified in RPFS is worthy of further study in PF treatment. Zhou and partners found that oral treatment with Hu-qi-yin (a prescription formulation) improved the body weight loss of rats compared with BLM-treated control group, and significantly reduced the over-expression of TGF-β1 protein and mRNA, inhibited the alveolitis and PF as reflected by the decrease of the Hyp levels of serum and lung, and amelioration of alveolitis and PF scores 28 days after BLM administration ([@bib161]). This work confirms that Hu-qi-yin administration by oral route possess protective and anti-fibrotic effects on BLM-induced PF in rats. Further studies are needed for clarifying the possible mechanisms of the protective and therapeutic effects of Hu-qi-yin as well as its active components.

Runfei decoction is composed of twelve kinds of herbs ([Table 3](#t0015){ref-type="table"}). A clinical work showed that Runfei decoction (200 ml daily to the end of radiotherapy) could significantly reduce the incidence of radioactive pneumonia and PF, decrease the serum levels of TGF-β and IL-6 in patients with lung cancer ([@bib80]) ([Table 4](#t0020){ref-type="table"}). It was observed that BLM (4 mg/kg)-treated rats with the treatment of Shenlong decoction (0.6, 1.2, 2.4 g/ml crude drug) decreased the mRNA levels of MMP-2 and TIMP-1, especially the former, and this action continued to the 28th day with Shenlong decoction (1.2 g/ml crude drug) decreasing most obviously ([@bib79]). Thus, Shenlong decoction may slow the progression of PF by maintaining the dynamic balance of MMP-2/TIMP-1 and reversing ECM deposition ([@bib79]). However, the role of Shenlong decoction on the pathological changes in lung tissue of murine PF is unclear. Besides, the main ingredients of Shenlong decoction need to be identified and are worthy of further study in PF treatment. Qingre Huoxue Sanjie formula (200 ml daily to the end of radiotherapy) has also been demonstrated safe and effective in alleviating the incidence of radioactive pneumonia and PF, relieving pathological symptoms, improving patient quality of life, decreasing the serum levels of IL-6, TNF-α and TGF-β1 in patients with lung cancer, esophageal cancer or thymoma but their chest radiotherapy must be identified ([@bib119]).

As TCM considers PF as a condition of *Lung* weakness due to lack of *Qi* that is the vigor for the respiration and the life as a whole, the authors used a new decoction for Strengthening *Qi* and Replenishing *Lung* (DSQRL) to treat experimental PF induced by carbon tetrachloride (CCl4) (1 ml/kg intra-peritoneally) in comparison with glucocorticoid treatment ([@bib152]). In the studies, four injections of CCl4 were carried out on the 1st, 5th, 9th and 14th days of the experiment; on day 17, the corresponding dose of DSQRL and prednisone acetate were given to the rats *via* a gastric feeding tube twice a day for another 30 days ([@bib152]) and 60 days ([@bib153]), respectively ([Table 4](#t0020){ref-type="table"}). It showed that DSQRL (9 g/kg raw herbs daily) with or without prednisone significantly reduced CCl4-induced increase of Hyp content in the lungs, decrease of cell counts in BALF, whereas prednisone alone did not; meanwhile, the growth rate and general conditions of the rats treated with DSQRL were better than the prednisone group ([@bib152]). Besides, DSQRL treatment (7.7 g/kg raw herbs daily) improved CCl4-induced abnormality of the lung surface morphology, had a significant alleviation in PF as illustrated by less inflammatory changes, cellular infiltration and collagen distribution, showed a significant reduction in TGF-β1 level ([@bib153]). These evidence show the potential merit of DSQRL holistic approach to treat PF. As CCl4 is toxic to experimental animals in particular to the liver rather than as a specific treatment for PF, it warrants to test the treatments of DSQRL on other PF models induced by other methods such as BLM or radiation. In addition, DSQRL is worth pursuing investigation further, in particular to find out the active ingredients and isolate active compounds by modern methods. Other data have shown that the lung fibrosis of mice appears between 14 and 28 days after a single-dose BLM application, and within 6 weeks, the lung repairs itself and minimal to no evidence of fibrosis remains ([@bib23]), if so, the work design of observing the role of 60 days treatment with DSQRL on PF may have room for improvement ([@bib153]).

Huqi Huoxue decoction has recently been proven evidently effective in treating PF patients ([@bib149]). The data showed that Huqi Huoxue decoction treatment has higher clinical curative effect, less adverse reaction and treatment cost than those in prednisone group ([@bib149]). However, the ratio of the compound was not provided and the dosage is unclear in the article. Huaxian formula contains thirteen herbs ([Table 3](#t0015){ref-type="table"}), which combined Western medicine could more improve the quality of life in patients with radiation-induced PF by reducing the respiratory symptoms, movement limitation, disease impaction and increasing the pulmonary function than the conventional Western medicine group ([@bib19]) ([Table 4](#t0020){ref-type="table"}). The optimized three-herb TCM formula, Modified Kushen Gancao (mKG) Formula, which is derived from the famous formula Kushen Gancao Tang, consists of three herbs ([Table 3](#t0015){ref-type="table"}). A recent study provided evidence that mKG formula significantly alleviated the collagen deposition (Masson staining) and alveolitis (HE staining), reduced the levels of IL-6, IL-17, TGF-β1 and Hyp, and lowered the expression of Col-I, Col-III and α-SMA in lung tissue of mice compared with BLM treatment ([@bib33]). This study not only demonstrate the anti-inflammatory properties of mKG, but also show some effects of regulating the ECM deposition and inhibiting the PF progression, and it may become an important method for preventing and treating PF.

The ethical Kampo formulation Sho-seiryu-to (TJ-19), a traditional medicine used throughout south-east Asia, is a mixture of eight herbal components ([Table 3](#t0015){ref-type="table"}). Yang and partners identified the constituents of TJ-19 including liquiritin and glycyrrhizin (originating from Glycyrrhiza Root), paeoniflorin and albiflorin (Paeony Root), schizandrin (Schisandra Fruit), cinnamic aldehyde and cinnamic acid (Cinnamon Bark) and 6-gingerol (Ginger Rhizome) by three-dimensional HPLC analysis ([@bib141]). In the study, TJ-19 was administered orally twice a day at a dose of 1.5 g/kg after intratracheal instillation of a single dose of BLM (5 mg/kg) in rats. TJ-19 treatment could prevent BLM-induced fibrotic changes in the lung histology, attenuate the loss in body weight, and increase in lung index and concentration of Hyp and MDA in the lungs induced by BLM ([@bib141]). Above effects were observed when TJ-19 administration was started 1 week before and simultaneously with the instillation of BLM. It suggests that TJ-19 has prophylactic potential against BLM-induced PF, and may therefore be a promising drug candidate and medicinal resource for preventing PF ([Table 4](#t0020){ref-type="table"}). Future work to examine the yield of the anti-oxidative components in TJ-19 and the curative as well as prophylactic effects of each constituent on PF are urgently needed.

Sun and partners observed that Tonifying Qi, Activating Blood and Dispersing Accumulation (TQABDA) method (one dose daily) combined with conventional glucocorticoids strategy not only more improve the symptoms but also inhibit lung alveoli and TGF-β1 level in identified PF patients than those treated with glucocorticoids only, but the included patients were not so clearly identified ([@bib115]) ([Table 4](#t0020){ref-type="table"}). It was also showed that oral Bufei Huoxue decoction (150 ml once, two times daily) in combination with oral prednisone had higher total effective rate and PaO~2~, lower symptomatic score and PaCO~2~, and more improved lung function (increased total lung capacity, vital capacity and carbon monoxide diffusion capacity), also no abnormal changes of blood, urine, and liver and kidney function were observed ([@bib136]). Similarly, Qingjin decoction (one dose daily) combined with conventional prednisone also more obviously improved the lung function, hypoxia, arterial blood gas related indicators in PF patients than those treated with prednisone only ([@bib134]). Yangyin Yiqi formula, contains 14 kinds of herbs, was recently demonstrated to effectively improve PF in patients with higher total effective rate (X-ray chest radiograph), FEV1 and FEV1/FVC(%), less serum TGF-β1 level, and shortened recovery time of night sweats, body emaciated, skin dryness, fatigue, loss of appetite and other symptoms after two weeks basic medication than those with oral prednisone treatment. Thus, it combination with glucocorticoids may reduce the dose of later and then alleviate the adverse effects to patients, but the applied dosage was not provided in the work ([@bib122]). Jade Screen Powder (100 ml once, two times daily) associated with prednisone more significantly improved the overall efficacy, curative effect (chest radiograph analysis), the quality of life (increased Karnofsky scores), lung function (increased FEV1, FVC, FEV1/FVC), and less serum TGF-β1 level in PF patients than the prednisone only strategy ([@bib144]). Though many clinical work showed that several formulas attenuated PF in patients, they contained so small sample sizes that further identification of its universal application may be more convince and necessary in different areas and hospitals.

Yupingfeng composes of three herbs in a dry weight ratio of 3:1:1 ([Table 3](#t0015){ref-type="table"}). It has been confirmed efficacious in preventing respiratory tract diseases ([@bib110]). Total glycoside of Yupingfeng (YPF-G), a mixture extracted from Yupingfeng, have anti-inflammatory, immunoregulatory ([@bib29]) and anti-fibrotic activities ([@bib66]). In a set of experiments, the authors showed that YPF-G containing astragaloside II and IV, could effectively attenuate the alveolitis and fibrosis induced by BLM, reduce the loss of body weight and increase of lung index, decrease the levels of Hyp, laminin, hyaluronic acid and Col-I, and down-regulate the over-expression of TGF-β1, inflammatory cytokine high-mobility group box 1 (HMGB1), and mesenchymal markers vimentin and α-SMA, but inhibited the decreased epithelial marker E-cadherin expression ([@bib66], [@bib22]). The authors also showed the anti-fibrotic effect of total polysaccharides of Yupingfeng (YPF-P) by reducing α-SMA-positive cells, TGF-β1 expression and the synthesis of Col-I, on BLM-induced rats ([@bib139]). These data suggest the therapeutic potential of Yupingfeng extracts (YPF-G and YPF-P) for PF, which were contributed to alleviating HMGB1 activity ([@bib66], [@bib22]), TGF-β1 activation ([@bib66], [@bib139]), as well as reversing EMT ([@bib22]) ([Table 4](#t0020){ref-type="table"}). Notwithstanding, the effects of Yupingfeng and its extracts have not been clarified in clinical and there is a need to fill in the blank.

Gao and partners carried out consequent studies to examine the anti-fibrotic effects and associated mechanisms of total glucosides of Danggui-Buxue-Tang (DBTG) on BLM-triggered pulmonary injury and fibrosis in rats ([@bib30], [@bib28], [@bib159]). As shown in the studies, DBTG administration attenuated BLM-induced alveolitis and lung fibrosis ([@bib30], [@bib28], [@bib159]), markedly reduced the weight loss and lung index ([@bib30]), decreased the elevated levels of hyaluronic acid, laminin, type III procollagen, Col-IV ([@bib28]), Col-I ([@bib30], [@bib159]), TNF-α ([@bib30]), TGF-β1 ([@bib30], [@bib159]) and α-SMA ([@bib159]), and decreased the mRNA levels of MMP-9 and TIMP-1 ([@bib28]). For oxidative stress indicators, DBTG restrained BLM-induced expression of NOX4, and blunted the decline in SOD activity, T-AOC, as well as the increase of MDA and 8-iso-prostaglandin in lung homogenates ([@bib159]). These findings provide evidence that DBTG may serve as a promising candidate to prevent lung fibrosis, which action may be attributed to the reduction of pro-inflammatory cytokines and ECM deposition, balancing the MMP-9/TIMP-1 system, and inhibiting NOX4 to control the level of oxidative stress ([Table 4](#t0020){ref-type="table"}). Nevertheless, the bioactive glucosides included in DBTG are still unknown and whether Danggui-Buxue-Tang and DBTG are effective in identified PF patients need to be proved with further investigations.

7. Future investigations of TCM in PF therapy {#s0105}
=============================================

PF sufferers generally undergo the patchy parenchymal inflammation, the reactive epithelial hyperplasia along with the transdifferentiation of FB to MFb, the formation of FB foci, basement membrane destruction, AEC apoptosis and excessive accumulation of ECM components ([@bib101], [@bib67]). Such diseases in humans are burdened by high incidence and mortality. Nevertheless, a number of therapies have been shown to be effective in animal studies to minimize damage, but to date no "magic bullet" has been widely recognized. At present, the only effective therapy for lung fibrosis in the clinical is lung transplantation but with significant risks and complications. Recently, a new drug pirfenidone has been approved for clinical use, however, it has only been able to slow the progression of the disease with unproven safety of long-term use ([@bib57]; [@bib62]). Thus, extensive efforts are still urgent need to develop novel strategies to prevent or cure PF.

As is known to all, the natural products of TCM provide a vast source for the discovery of new drugs, thus exploring these medicines may provide novel strategies for blocking fibrosis development. Moreover, the accepted knowledge of TCM should be its less side effects and wide range of pharmacological activities ([@bib44], [@bib107], [@bib126]; [@bib122]). Nowadays, accumulating data have shown that TCM as well as its bioactive extracts may offer an opportunity to identify new anti-fibrotic compounds. In the present review, we expound the laboratory and clinical advance of the active agents from single herb and TCM formulas in the treatment of PF, as shown in the Tables. As reported in considerable work, these bioactive extracts display defensive role against PF by repressing the abnormal activation signaling pathways (ROS/MAPK, TGF-β1/Smads, ACE-2/ANG(1--7), *etc*.) and regulating other associated mediators such as PDGF and HMGB1 ( [Fig. 2](#f0010){ref-type="fig"}).Fig. 2Emerging studies have shown the anti-fibrotic effects of the bioactive ingredients from TCM. The inflammatory cytokines release, oxidative stress, cell apoptosis, autophagy, EMT, several signaling pathways as well as other mediators are involved.Fig. 2

Over years, a number of animal PF models have been developed, and it provides important insights to understand the evolution of lung fibrosis and identify key cells, mediators, as well as the role of potential drugs based on molecular targets. The investigators have provided cumulative evidence of the protective role of TCM on PF in the models. There are also a fair number of clinical trials in PF using herbal medicines. From the collected data, these work are mostly published in Chinese language and some trials have methodological limitation and inconsistent identification of PF patients. Moreover, the conducted clinical trials only enroll dozens of patients and the clinical effects often combined with the Western medicines (mostly the glucocorticoids) as an adjuvant therapy by alleviating the PF symptoms or side effects without enough quantitative measurements, even some indicators were from the questionnaire and the dosage was not clearly provided. As the clinical researches of herb extracts are complex and some of which may have no bioactive or synergetic effects, the selected doses in clinical studies may be not enough to produce the best results. Thus, identification of the active constituents of herbs or the collaborative ingredients becomes a difficult but necessary task.

To better clarify the effectiveness of TCM and develop traditional medicines, the following concerns should be on the agenda:

First, the varied origin of herbs are often accompanied with different content of bioactive ingredients, so the use of genuine regional herbs on the related studies should be encouraged, and then the accumulated data of the same herb would be more valuable for an in-depth study. Besides, the methods to extract and analyze the active agents of TCM in different research groups or individuals are not always the same, particularly when studying the total extracts obtained from TCM which are extracted by different methods. Further, one major limitation of investigating the role of multi-components in TCM on PF is that the studies rarely specify which of the herbal compounds carry the main biological effect. Thus, the compared work between the total extracts of TCM and its potential active agents need to be conducted, from which we may distinguish the efficacy ingredients or the synergistic effects focusing on PF. Besides, the data are mostly positive effects and lack of herb toxicology researches. To partly circumvent the weaknesses, above critical recommendations should be paid attention and more trials should be designated.

Second, TCM and its active agents often exert protective role on PF *via* a plurality of targets as proven, which may be unlike that of chemical drugs. On the one hand, the anti-fibrotic agents of TCM with multi-targets may be a major advantage because the pathogenesis of PF involves a variety of mechanisms (inflammation, oxidative stress, cell apoptosis, *etc*.) and potential targets (TGF-β1, TNF-α, INF-γ, MMP-2, *etc*.). On the other hand, this event may mean more side effects due to the double-sided role of some targets in the progression of human diseases and health maintenance. However, herbal remedies have been used since ancient times, more often than not, some experimental data have shown that TCM sometimes have fewer adverse effects ([@bib44]; [@bib122]). The *in vitro* studies were mainly used for excavating the mechanisms of the extracts and their role is far from enough to present the true effects *in vivo*. In the light of these concerns, it should be an important part and more convincing to observe the affection for other organs or the whole body when exploring the anti-fibrotic effects of TCM in the lung.

Third, the pharmacological actions of TCM and the active agents in the researches of PF are not fully clarified, and the comprehensive evaluation in terms of the preclinical efficacy, optimal dose, toxicity evaluation and route of administration are still in its infancy. In addition, the mechanisms underlying the observed beneficial effects are widely unclear and their detailed investigation is challenging, especially the effective TCM formulas in clinical with few laboratory data, such as Huqi Huoxue decoction, Huaxian formula, Bufei Huoxue decoction and Qingjin decoction ([@bib19], [@bib134], [@bib136], [@bib149]). Even if there are studies exploring considerable mechanisms, they neglect to observe the impact of these agents on the quality of animal life including the respiratory function, body weight, appearance and lifetime, which are the most basic but important clinical outcomes for the therapy of PF patients. The functional analysis of fibrotic lungs after the treatment of TCM as well as the active agents should be performed in experiments based on the successfully established PF models. More often than not, the associated studies lack the discussion of the experimental results and the ideas for further researches. Besides, the neglect in validating the experimental reagents (specifically cell lines and antibodies), inappropriate experimental design and execution, investigators' bias, and misuse of statistical procedures are major causes of data irreproducibility ([@bib85], [@bib86]). These drawbacks undoubtedly contribute to the slow development of Chinese herb medicine in PF. Therefore, it will be extremely demanding to enrich the studies from the research design to perform conclusive mechanistic analysis on these medications.

Fourth, the application of animal models has provided critical insights in understanding the pathogenesis of PF and the development of potential drugs. It has shown that BLM, irradiation and LPS are commonly used inducers of PF in animals, whereas BLM plays a major role. In clinical, BLM is effectively against abroad spectrum of cancers, but its use is often limited due to the main detrimental effects of inducing PF on patients ([@bib38]). Thus, BLM is considered to be an ideal tool for imitating lung fibrosis. It can be administrated intraperitoneally, intravenously, subcutaneously or intratracheally but intravenous (iv) and intratracheal (it) are the more commonly used routes. Notably, there are emerging concerns about BLM model regarding its high reproducibility and the ability to mimic the PF-like phenotypes and histologic features observed in patients treated with BLM. This PF model can be divided into three stages including injury, inflammation and fibrosis ([@bib84]). BLM administration (often starting early within −1 to 0 days before the potential drugs treatment) may show effects on fibrosis due to anti-inflammatory activity within two weeks, while the followed fibrotic events appear only between the third and fourth week ([@bib24]). Unfortunately, in the murine model, lung fibrosis appears between 14 and 28 days after a single-dose administration of BLM, but the lung repairs itself and minimal to no evidence of fibrosis remains within 6 weeks ([@bib23]). Moreover, human PF is a chronic pathological process where epithelial injury, inflammation, mal-regeneration and fibrosis co-exist, and the result of repeated insults to the alveolar epithelium ultimately cause progressive and irreversible fibrosis, which is not parallel to animal models ([@bib40], [@bib84], [@bib99]).

These events mean that BLM model can only partially recapitulate PF and maybe not ideal for long-term studies. Furthermore, a majority of the herbs are administrated in the early period of BLM-induced inflammation rather than in the phase of formed PF, in other words, it is not clear whether the reported 'anti-fibrotic' effects are due to true inhibition of fibrosis or rather the result of reduced lung inflammation. It may be one reason that only very few experimental studies of potential drugs eventually into the clinical applications. Fortunately, the investigated agents of TCM and "Western drugs" in the emerging studies may have shown potential protective role, at least, on cancer patients that suffer from the adverse effects of BLM, which is also meaningful. As different models have varied processes of PF-like changes and the periods of successful establishment of PF is not the same yet. The animal models cannot truly mimic the general situations of human diseases including PF, but such models indeed provide accumulated evidence for further survey of the effective or toxic roles in clinical. In future studies, more exploration of TCM and the active agents on the formed PF models is urgent need. Furthermore, alternative or combined models of PF should be recruited to confirm the pharmaceutical property of the active agents of TCM for supplement, either by chemical induction or using transgenic animals ([@bib60], [@bib83]).

Fifth, in view of the similar pathological mechanisms of tissue fibrosis, it can be noted that these TCM, which is effectively used for PF, may have benefits on other fibrotic disorders. Tissue fibrosis shares the core features including epithelial and endothelial injury and dysfunction, abnormal proliferation of MFb, smooth muscle cells and stellate cells, ECM deposition, and immune cell recruitment ([@bib68]). A variety of identical cytokines (such as TNF-α and HMGB1), growth factors (such as TGF-β1), and angiogenic factors (such as VEGF) have been confirmed to regulate the fibrogenesis in diverse organ systems including liver, kidney, lung, and myocardial. Thus, it is tempting to identify the pharmacological activities of these potential active agents in single herbs and TCM formulations on other organ fibrosis by the correlative mechanisms of PF, all of which are aimed to look for effective anti-fibrotic drugs.

Last but not least, in light of the complicated ingredients of TCM, especially the herbal formulations, exploring the potential agents against PF is a daunting work. Above all, if the ingredient is a monomer from TCM, we need to first provide enough evidence to prove its anti-fibrotic role in the animal and/or cell models. To enhance the benefits and weaken the side effects, appropriate structural improvement of potential effective agents from TCM might be of certain value, and then the comparative experiments should be carried out among the derivatives. In the present review, we have shown the effective monomers from single herbs, including naringin, glycyrrhizic acid, curcumin, *etc*., which are classified by their special structures and thus may be helpful for further design of these agents in developing innovative drugs for PF treatment. Meanwhile, if the anti-fibrotic agents is a mixture from TCM, we need to conduct a series of work for comparing the activities of the two monomers, one definite monomer to the total extracts or whole formula, as well as several definite monomers with different ratio, *etc*., based on the enriched signaling pathways involved in PF. Here, to guide these pharmacologic work, the "network pharmacology" strategies is urgent needed ([@bib95], [@bib160]).

Currently, the pharmacologic dogma, \"single drug, single target, single disease\", is at the root of the lack of drug productivity. Low drug productivity has been a significant problem for several decades even though numerous novel technologies were introduced during this period ([@bib95]). From a systems biology viewpoint, "network pharmacology", a hot spot that is utilized to construct the bioactive ingredient-target networks of herbs, is particularly suitable for the investigations of the bioactivity spectrum of TCM and the underlying mechanisms in PF ([@bib55], [@bib97], [@bib130]). Therefore, to elucidate the pharmacological characteristics and mechanism of action of the formulas such as Hu-qi-yin, Shenlong Decoction, Decoction for Strengthening *Qi* and Replenishing Lung, and Sho-seiryu-to, more studies should be conducted on the effects and chemical profiles (including bioactive ingredients) to investigate the network of the role in the prevention and cure of PF before the follow-up trails in large amount of PF patients. Besides, combining these perspectives with the new era of genetic modifiers identification may provide new insights into potential drugs for treating the severity of the fibrotic lung disease ([@bib37]).

8. Conclusion {#s0110}
=============

The collected data have shown the therapeutic benefits of TCM on PF, and TCM may serve as an essential supplement for the treatment strategy of PF. However, more continued work should be undertaken to clarify the unconfirmed chemical composition and regulatory mechanisms, conduct standard clinical trials, and evaluate the possible side effects. The research progress and views provided in this review will be helpful for future exploration of TCM in the development of PF therapy, and gain more reliable and reproducible data.
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[^1]: AEC: alveolar epithelial cells; AMs: alveolar macrophages; Andro: Andrographolide; BLM: bleomycin; CCl4: carbon tetrachloride; CP: cyclophosphamide; EGCG: epigallocatechin-3-gallate; ESA: eclipta saponin A; ET: endothelin; FB: fibroblasts; GCA: glycyrrhizic acid; HELFs: human embryonic lung fibroblast; HLF: human lung fibroblasts; HPMECs: human pulmonary microvascular endothelial cells; HSYA: hydroxy safflor yellow A; IR: irradiation; LPS: lipopolysaccharide; MFb: myofibroblasts; PF: pulmonary fibrosis; PMVEC: pulmonary microvascular endothelial cells; PQ: paraquat; SAA: salvianolic acid A; Tan IIA: tanshinone IIA; TGF-β1: transforming growth factor-β1; THP: tetrahydropalmatine

[^2]: CP: cyclophosphamide; FB: fibroblasts; GC-MS: gas chromatograph-mass spectrometer; GSH: glutathione; HC: Houttuynia cordata; IFN: interferon; iNOS: inducible nitric oxide synthase; PF: pulmonary fibrosis; LDH: lactate dehydrogenase; LPS: lipopolysaccharide; NS: Nigella sativa; SARS, severe acute respiratory syndrome; SP-D: surfactant protein-D; TGF-β1: transforming growth factor-β1; TNF-α: tumor necrosis factor-α

[^3]: DBTG, total glucosides of Danggui-Buxue-Tang; DSQRL, decoction for Strengthening Qi and Replenishing Lung; mKG, Modified Kushen Gancao; TJ-19, Sho-seiryu-to; TQABDA, Tonifying Qi, Activating Blood and Dispersing Accumulation; YPF-G, total glycoside of Yupingfeng; YPF-P, total polysaccharides of Yupingfeng

[^4]: BLM: bleomycin; CCl4: carbon tetrachloride; DSQRL: Decoction for Strengthening Qi and Replenishing Lung; ECM: extracellular matrix; ELSD, evaporative light scattering detector; EMT: epithelial-mesenchymal transition; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; GC, gas chromatography; GPC, gel permeation chromatography; HMGB1: high-mobility group box 1; HPLC, high-performance liquid chromatography; Hyp: hydroxyproline; IL: interleukin; MDA: malondialdehyde;; mKG: Modified Kushen Gancao Formula; MMP: matrix metalloproteinase; MS, mass spectrometry; NF-κB: nuclear factor kappa B; PF: pulmonary fibrosis; QTOF, quadrupole time-of-flight; TGF-β1: transforming growth factor-β1; TIMP: tissue inhibitor of metalloproteinase; TJ-19, Sho-seiryu-to; TNF-α: tumor necrosis factor-α; TQABDA, Tonifying Qi, Activating Blood and Dispersing Accumulation; UPLC, ultraperformance liquid chromatography; YPF-G, total glycoside of Yupingfeng; YPF-P, total polysaccharides of Yupingfeng; α-SMA: α-smooth muscle actin
